A long-running partnership between digital therapeutics (DTx) developer Sidekick Health and Pfizer has resulted in a new app to support patients with atopic dermatitis, which will start rolling ...

Founded in 2019, Brexogen is a biotechnology company pioneering Natural Biomacromolecule Cargo-Controlled Exosome Technology for therapeutics, medical devices, and aesthetic applications. The ...

Premorbid allergic diseases are linked with the development of age-related macular degeneration (AMD), however, the risk of allergic diseases among patients with AMD is largely unknown.To evaluate the ...

including Pfizer in the area of atopic dermatitis and Bayer in peripheral artery disease. It also has a partnership with health insurance company Anthem, providing digital-based care programmes ...

If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025Priority ...

Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoidIf approved, Dupixent would be the first and only ...

Years of translational research have successfully improved treatment outcomes for common dermatological conditions such as ...

If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025 Priority Review granted based on positive pivotal results demonstrat ...

Lameness remains one of the top health issues dairy farms battle, and it is also a serious animal welfare concern.

Q2 2025 Management View Brad O'Connor, CEO, highlighted the company’s record revenue of $23.9 million for the first half of FY 2025, driven by a 27% growth in clinical trials revenue compared to the ...